RBC Capital Maintains Outperform on Boston Scientific, Raises Price Target to $61
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh maintains an 'Outperform' rating on Boston Scientific (NYSE:BSX) and raises the price target from $58 to $61.
September 21, 2023 | 3:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific's price target has been raised from $58 to $61 by RBC Capital, maintaining an 'Outperform' rating.
The raised price target and maintained 'Outperform' rating by RBC Capital indicates a positive outlook for Boston Scientific. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100